Tim Kennedy

[Novartis News @NovartisNews]

Novartis announces topline data from Phase III trial of complement inhibitor in paroxysmal nocturnal hemoglobinuria (PNH) – a rare and serious blood disorder #NovartisNews

[Novartis Cancer @NovartisCancer]

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder that heavily hinders patients’ quality of life, and may be associated with significant barriers to care - from diagnosis to treatment. Learn more about our research in PNH https://t.co/HZGWJgk9kV. #PNH

[Antonio Giordano, MD PhD @antgiorda]

No improvement in PFS with fulvestrant-palbo
over letrozole-palbo among patients receiving
frontline systemic treatment for endocrine-sensitive, HR+HER2- MBC. NSAI are preferred partner in this setting. The phase II PARSIFAL study published on @JAMAOnc https://t.co/W4ztxiuDV3

[Vas Narasimhan @VasNarasimhan]

To improve human health, we must also protect and improve the health of our planet. @Novartis is proud to be part of the #RacetoZero—the world’s largest alliance of non-state actors committed to halving emissions. https://t.co/OEQIlW1aDH

[Mauricio Cuello @mcuellot]

Actualizacion en ESMO del estudio Monaleesa-2. El ribociclib aumenta la sobrevida global mas de un año. En Uruguay se mantienen los problemas de cobertura y acceso a este farmaco. Debemos trabajar por una solucion.

[Omar Alhalabi, MD @OAlhalabiMD]

#ESMO21 @myESMO Exciting to our field of #oncology to see the median survival improve to >5 years in both hormone sensitive breast cancer (ribociclib MONALEESA-2 data) and hormone sensitive prostate cancer (PEACE-1 data).

[Mindy @MinThomp]

I wish more doctors would prescribe Kisqali/ribociclib instead of jumping to Ibrance. I'm on cycle 53 (4 and 1/2 years) of Kisqali and it's my first line of treatment since diagnosis.

[Medscape Oncology @MedscapeOnc]

The first report of a median OS exceeding 5 years in a phase 3 trial for advanced #breastcancer comes from the MONALESSA-2 trial with ribociclib and letrozole. https://t.co/DNPifEfY8r #ESMO21

[Dr Sarah Sammons @drsarahsam]

First report of median survival surpassing 5 years in metastatic HR+/HER2- breast cancer with ribociclib/AI! - Dr. Hortobagyi

To our patients living with MBC, this is still not enough, but continued incremental improvements help.

@OncoAlert #bcsm @myESMO

[Vivek Subbiah, MD @VivekSubbiah]

⭐️🚨 The @myESMO #ESMO21 Sunday morning breaking news slide👉🏼MONALEESA-2: RIBOCICLIB + AI in 1L postmenopausal patients by our @MDAndersonNews legendary researcher in breast cancer -Dr. Gab Hortobagyi.
👉🏼At a median follow-up of 80 months. OS curve of the day ! @OncoAlert

[Antonio Giordano, MD PhD @antgiorda]

CDK4/6 inhibitor Ribociclib plus endocrine therapy (letrozole) improved the overall survival in the first line setting for ER+ HER2- #MBC patients. We can now tell our patients "OVER 5⃣ YEARS" #ESMO2021 Dr. Hortobagyi #bcsm

[Vivek Subbiah, MD @VivekSubbiah]

🚨⭐️ Sunday @myESMO #ESMO21 highlight 📢 From @MDAndersonNews own legend Dr. Gab Hortobagyi➡️The MONALEESA2 trial with CDKi inhibitor
👉🏼AI +/- ribociclib for 1L metastatic HR+ breast cancer
👉🏼Improvement in OS (63.9 mo vs 51.4 mo, HR 0.76)
✅OS now exceeds 5 yrs! @OncoAlert

[Sara Tolaney @stolaney1]

Monaleesa-2: AI +/- ribociclib for 1L metastatic HR+ breast cancer. Improvement in OS seen (63.9 mo vs 51.4 mo, HR 0.76); OS now exceeds 5 yrs!

@myESMO @OncoAlert

[G Curigliano MD PhD @curijoey]

OS benefit with ribociclib and endocrine therapy in endocrine sensitive ER positive MBC with survival rate of 44%!

[Scott Tagawa @DrScottTagawa]

177Lu-PSMA-617 with protocol-defined SOC superior to SOC alone in pre-treated mCRPC with PSMA uptake in metastases #pcsm #ASCO21

[Manuel Muro @manuelmuro5]

La combinación de ribociclib, inhibidor de ciclo celular a nivel de CDK4/6 y ciclina D1 (Novartis, Kisqali), con fulvestrant, degradador del receptor de estrógeno, mejora la supervivencia de mujeres postmenopáusicas con cáncer de mama metastásico HR+/HER2-
https://t.co/Z5ipuMeiTS

[Matteo Lambertini, MD PhD @matteolambe]

Metastatic #BreastCancer Oral Abstract Session at #ASCO21: final analysis of #MONALEESA3 (#fulvestrant with or without #ribociclib)...really great data but please don't stop trial follow-up with median #OS not yet reached in first-line treated patients

@OncoAlert #bcsm @ASCO

[Jame Abraham, MD, FACP @jamecancerdoc]

Almost 20 months delay in starting chemo in ER positive metastatic #breastcancer by adding ribociclib to fulvestrant - median overall survival improvement of 12 months in 56.3 months follow up ⁦@OncoAlert⁩ #ONCOALERT #ASCO21

[Hope Rugo @hoperugo]

Slamon ML3 @asco21 ribo fulvestrant improves OS in first and second line setting. Remarkable progress in most common BC subset. Imp to keep in mind that E sensitivity is not comparable in 1st line vs heavily pretreated @oncoalert